Eplerenone did not increase adverse events compared with placebo in acute HF. Importantly, disease severity and comorbidity burden greatly influence adverse events, but not benefit from eplerenone.
Keyphrases
- acute heart failure
- end stage renal disease
- heart failure
- ejection fraction
- newly diagnosed
- chronic kidney disease
- liver failure
- prognostic factors
- peritoneal dialysis
- randomized controlled trial
- clinical trial
- intensive care unit
- respiratory failure
- double blind
- aortic dissection
- acute respiratory distress syndrome